AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31503274
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (3g daily)
Trial: 24383914
Drug: Vi vaccine
RxNorm normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi vaccine (Typherix(®))
Trial: 24383914
Drug: Ty21a vaccine
RxNorm normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a vaccine (Vivotif(®))
Trial: 15849398
Drug: Antibiotics (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (group A)
Trial: 15849398
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (group B)
Trial: 9257789
Drug: D5159 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5159 (8 mg)
Trial: 8421248
Drug: Caffeine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3.0 mg/kg
Trial: 8421248
Drug: Placebo (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.0 mg/kg caffeine)
Trial: 31327292
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly group-exercises and physical activity counselling
Trial: 29421002
Drug: Edoxaban-based strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban-based strategy (60 mg or 30 mg once daily) plus P2Y12 antagonist (clopidogrel, 75 mg once daily) for 12 months
Trial: 29421002
Drug: VKA-based strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA-based strategy (VKA plus P2Y12 antagonist and acetylsalicylic acid 100 mg once daily) for 30 days to 12 months
Trial: 27480131
Drug: CPP‐1X 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP‐1X 750 mg and sulindac 150 mg
Trial: 27480131
Drug: CPP‐1X placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP‐1X placebo and sulindac 150 mg
Trial: 27480131
Drug: CPP‐1X 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP‐1X 750 mg and sulindac placebo
Trial: 17198904
Drug: C12 Peptide
RxNorm normalized name: C12:0
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C12 Peptide (3.8 g daily for 4 weeks)
Trial: 12603176
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg twice daily for 5.5 days
Trial: 12603176
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg once daily for 6 days
Trial: 12603176
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg twice daily and Simvastatin 40 mg once daily
Trial: 9096658
Drug: Etoposide (VP-16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide (VP-16) >4,000 mg/m2
Trial: 29185087
Drug: Assistive devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assistive devices for daily life activities
Trial: 27548766
Drug: Enalapril-folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid daily, n=7545)
Trial: 27548766
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg daily, n=7559)
Trial: 25335675
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (20 g per day)
Trial: 20492851
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) at 10 mg for 1 week and then 20 mg for 1 week
Trial: 19057627
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Trial: 16643445
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (including autologous stem cell transplantation) for patients <60 years
Trial: 16643445
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (including autologous stem cell transplantation) for patients aged 60-64 years
Trial: 8772604
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin (200 IU daily for 5 days/week) plus 1000 mg calcium daily
Trial: 26119844
Drug: Calcium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alone (1000 mg daily)
Trial: 1630044
Drug: Regular beta-agonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular beta-agonist inhalation
Trial: 1630044
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required beta-agonist inhalation
Trial: 31592623
Drug: 3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/kg of CHO beverage
Trial: 16766544
Drug: Isoflavone-containing soy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-containing soy-based nutritional supplements for 8 weeks
Trial: 11422000
Drug: Anastrozole (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (7 mg loading dose on day 1, followed by 1 mg daily on days 2-11)
Trial: 3573541
Drug: L-triiodothyronine (T3)
RxNorm normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-triiodothyronine (T3) treatment
Trial: 3573541
Drug: Sodium ipodate
RxNorm normalized name: ipodate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ipodate treatment
Trial: 28724041
Drug: Rhubarb (30.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb (30.0 g/d) for 7 days
Trial: 28724041
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for 7 days
Trial: 25542311
Drug: ABVE‐PC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVE‐PC + 21 Gy involved field radiation therapy (IFRT)
Trial: 23680435
Drug: Escitalopram (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (dose range around 10-15 mg/d)
Trial: 15080852
Drug: Patient-controlled on-demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled on-demand treatment with esomeprazole, 20 mg daily
Trial: 15080852
Drug: General practitioner-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 2 weeks
Trial: 15080852
Drug: General practitioner-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 4 weeks
Trial: 2475323
Drug: Opioid meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid meperidine (150 mg, p.o.)
Trial: 2475323
Drug: Antidepressant imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant imipramine (100 mg, p.o.)
Trial: 780063
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg oxprenolol daily
Trial: 780063
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg diazepam daily
Trial: 27161285
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing Cichorium intybus root extract with UV filters
Trial: 27161285
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing Cichorium intybus root extract without UV filters
Trial: 27161285
Drug: Vehicle formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle formulations containing UV filters
Trial: 27161285
Drug: Vehicle formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle formulations without UV filters
Trial: 25626920
Drug: Intralesional bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional bleomycin (1 mg/mL) for three consecutive months
Trial: 25626920
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (10 mg/mL) for three consecutive months
Trial: 25626920
Drug: Intralesional bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional bleomycin (1 mg/mL)
Trial: 25626920
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (10 mg/mL)
Trial: 21546927
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein breakfast (NP; 18 ± 1 g protein)
Trial: 21546927
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein breakfast (HP; 50 ± 1 g protein)
Trial: 20396724
Drug: Poetam and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poetam and anaferon (pediatric formulation) administered in combination with iron preparation
Trial: 11451697
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg orally once daily
Trial: 11451697
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg orally once daily
Trial: 10052247
Drug: Etoposide 80
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 80 mg/m2 day 1-3, folinic acid 100 mg/m2 day 1-3, 5-fluorouracil 340 mg/m2 day 1-3, and epirubicin 60 mg/m2 day 1, repeated every three weeks
Trial: 24444280
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus desmopressin (0.3 μg/kg)
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment at 2.2 bar
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment at 2.5 bar
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment (both protocols)
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment with positive expectation
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment with indifferent expectation
Trial: 17274312
Drug: HBO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBO2 treatment with negative expectation
Trial: 12599053
Drug: Rhesus monkey
RxNorm normalized name: rabies vaccine,adsorbed,rhesus monkey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus monkey rotavirus-based quadrivalent vaccine (4 x 10^5 plaque-forming units/dose)
Trial: 12599053
Drug: Rhesus monkey
RxNorm normalized name: rabies vaccine,adsorbed,rhesus monkey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus monkey rotavirus-based quadrivalent vaccine
Trial: 8841152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan 1 hour before 50 mg quinidine
Trial: 8841152
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg quinidine
Trial: 8841152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan (poor metabolizers)
Trial: 8841152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan (extensive metabolizers with quinidine)
Trial: 8841152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan (extensive metabolizers)
Trial: 1738578
Drug: Vibratory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibratory stimulation with naloxone (0.4 mg)
Trial: 27655761
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (HFM) - 250 mL (520 kcal) consisting of rapeseed oil (440 kcal), emulsifier, sucrose, flavor cocktail
Trial: 11783207
Drug: CHM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM plus chemotherapy
Trial: 11783207
Drug: Single chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single chemotherapy
Trial: 1768539
Drug: Low-dose adrenaline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adrenaline infusions
Trial: 1768539
Drug: Phenylephrine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusions
Trial: 29858149
Drug: Moxidectin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (8 mg) plus Albendazole (400 mg)
Trial: 29858149
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) plus Oxantel Pamoate (25 mg/kg)
Trial: 29858149
Drug: Moxidectin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (8 mg) plus Tribendimidine (200 mg or 400 mg)
Trial: 29858149
Drug: Moxidectin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (8 mg) alone
Trial: 10873672
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (400 mg/day for 5 weeks)
Trial: 7680374
Drug: Pamidronate (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (high dose 600 mg/d and low dose 300 mg/d)
Trial: 7680374
Drug: Pamidronate (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (low dose 300 mg/d)
Trial: 27318866
Drug: Dual low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual low-density lipoprotein cholesterol-lowering therapy (DLLT) with statin-ezetimibe combination
Trial: 22181006
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 0.05 μg/kg/min
Trial: 22181006
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 0.08 μg/kg/min
Trial: 22181006
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 0.10 μg/kg/min
Trial: 20105045
Drug: Bolus administered
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administered 15 min before meal
Trial: 20105045
Drug: Bolus administered
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administered just before meal
Trial: 20105045
Drug: Bolus administered
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administered just after meal
Trial: 10073326
Drug: Trimetrexate, leucovorin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetrexate, leucovorin, and dapsone administered for 21 +/- 3 days; trimetrexate glucuronate, 45 mg/m2; leucovorin, 20 mg/m2; dapsone, 100 mg daily
Trial: 2291659
Drug: Cefmetazole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole 0.5 g
Trial: 2291659
Drug: Cefmetazole 1
RxNorm normalized name: cefmetazole 1 g/50 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole 1 g
Trial: 2291659
Drug: Cefmetazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (all doses)
Trial: 31704504
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) + full-mouth ultrasonic scaling (FMUS)
Trial: 25872653
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behaviour therapy (TF-CBT)
Trial: 24672232
Drug: C. domestica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. domestica extracts 1,500 mg/day for 4 weeks
Trial: 24672232
Drug: Ibuprofen 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 1,200 mg/day for 4 weeks
Trial: 20683042
Drug: Clonazepam (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion)
Trial: 17055120
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (7.2 g/day, providing 1.1 g/day of 20:5 (n‐3) and 0.7 g/day of 22:6 (n‐3) fatty acids)
Trial: 10465179
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (15 mg/day) for 6 weeks
Trial: 7611726
Drug: Transfemoral, venous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfemoral, venous intradural infusions of urokinase
Trial: 2171332
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens (Premarin) 50 mg daily
Trial: 6123336
Drug: Fentanyl 0.0066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.0066 mg kg‐1 i.v. (group A)
Trial: 6123336
Drug: Fentanyl 0.0066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.0066 mg kg‐1 i.v. followed by almitrine 0.5 mg kg‐1 i.v. (group B)
Trial: 6123336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of almitrine 0.5 mg kg‐1 and fentanyl 0.0066 mg kg‐1 (group C)
Trial: 22134132
Drug: Solanezumab (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanezumab (0.5, 1.5, 4.0, and 10.0 mg/kg)
Trial: 19864308
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion maintained at a target organ concentration of 1.5 ng ml‐1 until extubation
Trial: 19864308
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (remifentanil infusion stopped at the end of surgery)
Trial: 16319704
Drug: Treatment provided
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment provided to high-stress group
Trial: 16319704
Drug: Treatment provided
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment provided to low-stress group
Trial: 16319704
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment satisfaction for all patients
Trial: 7659811
Drug: Misoprostol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (50 mcg vaginal tablet)
Trial: 2444306
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg bd)
Trial: 12473698
Drug: 1.50 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.50 mg/mL rhBMP-2
Trial: 24357574
Drug: 1-day cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day cognitive-behavioural therapy (CBT) self-confidence workshops
Trial: 20597564
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight
Trial: 20597564
Drug: 180 microg
RxNorm normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily
Trial: 18414360
Drug: Midazolam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.04 mg/kg)
Trial: 27350144
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection
Trial: 10325515
Drug: Combined endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined endocrine therapy for 3 or 6 months
Trial: 2015969
Drug: recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant DNA hGH (rhGH; 0.1 mg.kg‐1.day‐1)
Trial: 2015969
Drug: prednisone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone (0.8 mg.kg‐1.day‐1)
Trial: 2015969
Drug: rhGH and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH and prednisone (combined treatment)
Trial: 26854877
Drug: Removable partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable partial dentures (n = 53) or implant‐supported fixed partial dentures (n = 19)